Jafron Biomedical Co.,Ltd. (SHE:300529)

China flag China · Delayed Price · Currency is CNY
18.71
-0.27 (-1.42%)
At close: Mar 9, 2026
-25.84%
Market Cap 14.49B
Revenue (ttm) 2.04B
Net Income (ttm) 481.79M
Shares Out 774.36M
EPS (ttm) 0.63
PE Ratio 29.72
Forward PE 26.45
Dividend 0.80 (4.21%)
Ex-Dividend Date May 26, 2025
Volume 5,212,316
Average Volume 4,556,583
Open 18.90
Previous Close 18.98
Day's Range 18.52 - 18.90
52-Week Range 18.52 - 27.21
Beta 0.43
RSI 30.68
Earnings Date Apr 28, 2026

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/buc... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1989
Employees 2,500
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300529
Full Company Profile

Financial Performance

In 2024, Jafron Biomedical's revenue was 2.68 billion, an increase of 39.27% compared to the previous year's 1.92 billion. Earnings were 820.20 million, an increase of 87.91%.

Financial Statements

News

There is no news available yet.